GLP-1 Drugs in Children Ages 8-11: Trends

A 3.52-million-child study published in Pediatrics on 4 September 2026 put the first hard numbers on something clinicians and parents have been noticing: GLP-1 receptor agonists are reaching children who are younger than any drug in the class is approved for.^[1] The researchers, led by Babak J. Orandi and colleagues at NYU, pulled prescription records from the Epic Cosmos database covering children ages 8 to 11 with obesity but without diabetes, from January 2019 through June 2026.^[1] The headline: prescribing grew 310-fold over that period, from 0.03% of eligible children in 2019 to 9.3% by 2026, yet the overall share who received any GLP-1 prescription across the full study window was still only 0.6%.^[1]

What the numbers say

Among 3,520,531 children ages 8 to 11 with obesity and no diabetes, Orandi et al. identified three medications on prescription: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).^[1] All three are FDA-approved for weight management, but the minimum approved age for each is 12, not 8.^[2] Prescriptions in the 8-to-11 group therefore represent off-label use within an already-selective practice pattern.

Clinicians appear to be triaging by risk. Children with obesity-related comorbidities received prescriptions at a rate of 188.9 per 10,000, roughly four times the rate seen in children without comorbidities.^[1] Older children within the cohort fared differently from younger ones: 11-year-olds received prescriptions at 79.5 per 10,000, compared to 41.5 per 10,000 for 8-year-olds.^[1] Girls received prescriptions more often than boys (75.9 versus 42.8 per 10,000).^[1]

The socioeconomic gradient runs in an unexpected direction. Children from lower-vulnerability households received more prescriptions than those from higher-vulnerability backgrounds: 76.1 versus 49.2 per 10,000.^[1] The authors flag this as a disparity worth watching, since childhood obesity itself is more prevalent in lower-income communities in the US.^[3]

The regulatory backdrop

None of the three drugs named in the study are cleared by the FDA for this age group. Saxenda (liraglutide) received FDA approval for pediatric weight management in 2020, with a minimum age of 12.^[2] Wegovy (semaglutide 2.4 mg) followed in December 2022, again for ages 12 and older.^[4] Zepbound (tirzepatide) was approved for adults with obesity in November 2023; no pediatric weight-management approval exists for tirzepatide as of this writing.

The FDA-approved lower bound stops at 12 for a practical reason: the pivotal trials for pediatric weight management enrolled adolescents, not younger children. A 2023 trial in NEJM of liraglutide in children ages 6 to 11 did establish proof of concept for younger cohorts^[5], but GLP-1 approvals for children under 12 remain absent as of September 2026. For a complete regulatory picture on each drug by country, see the tirzepatide regulation pages and the overview of semaglutide regulatory status.

Why prescribing is rising despite the age gap

The American Academy of Pediatrics 2023 clinical practice guideline on childhood obesity recommended intensive, multi-component treatment and for the first time explicitly supported pharmacotherapy for adolescents.^[6] The guideline covers ages 12 and older for GLP-1 class drugs, consistent with approvals, but it moved the professional culture away from watchful waiting and toward earlier intervention. That cultural shift, combined with the visible efficacy signal from adult trials, likely contributed to extending prescribing into the 8-to-11 band as well.

Off-label prescribing is legal in the US and common in paediatrics generally; clinicians regularly use medications outside approved ages when the clinical rationale is strong and the risk profile is understood. The open question is whether the risk profile for this age group is understood well enough. Cardiovascular, gastrointestinal, and growth-related effects across multi-year follow-up in younger children have not been characterised in the same depth as in adult trials.

What this is not

A signal that prescribing is reckless. The 0.6% overall rate across the full study window, and the four-to-one ratio favouring children with comorbidities, both suggest selectivity rather than broad adoption. The 310-fold growth in rate is striking on a percentage basis, but the absolute starting point was 0.03%, so the number of children involved at the earliest time points was very small.

Not a call for children to seek these medications. The drugs involved are prescription-only and require a prescribing clinician who can weigh individual cardiovascular risk, gastrointestinal tolerability, potential effects on linear growth, and the family's capacity for the monitoring these regimens require. Nothing in this analysis changes that.

Not a peer-reviewed trial of efficacy or safety in 8-to-11-year-olds. The Orandi study tracked prescription rates from administrative data. It did not report weight outcomes, adverse events, or discontinuation rates in this cohort.

Where this lands

A 310-fold increase in any prescribing category over seven years would be notable. In an age group younger than any drug's approved label, it is a data point regulators, paediatric endocrinologists, and health equity researchers will want to track prospectively. The socioeconomic access gap is the clearest short-term policy question: the children with the highest obesity prevalence are not the ones getting the prescriptions.^[1]

For families, the more immediate questions are clinical ones: whether a specific child's comorbidity burden justifies off-label use, and whether a clinician experienced in paediatric obesity medicine is involved in that decision. The literature does not yet provide the age-8 efficacy and safety data that would answer those questions at the population level.